Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00512798 · ClinicalTrials.gov registry record · Phase 1
Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
A Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00512798 is a Phase 1 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 47 participants.
The verdict
NCT00512798, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving temozolomide together with bortezomib may kill more tumor cells. PURPOSE: To determine the best dose of bortezomib and temozolomide and to see how well they work in treating patients with advanced refractory solid tumors or melanoma.
Interventions
- DRUG Temozolomide
- DRUG temozolomide
- OTHER immunoenzyme technique
- DRUG PS-341 (VELCADE)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2003-06 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00512798
The ClinicalTrials.gov registry entry for NCT00512798 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Temozolomide is the first listed.
NCT00512798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00512798 about?
NCT00512798 is a clinical study titled "Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma". RATIONALE: Drugs used in chemotherapy, temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving temozolomide togethe...
What is the current status of trial NCT00512798?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2003-06. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00512798?
The interventions under investigation include: Temozolomide (DRUG), temozolomide (DRUG), immunoenzyme technique (OTHER), PS-341 (VELCADE) (DRUG).
Who is sponsoring clinical trial NCT00512798?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.